ARVN vs BMRN · rev $265.3M vs P/E 40, rev $1.76B
Arvinas Inc (ARVN) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Arvinas Inc (ARVN) is a biotechnology company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported ARVN revenue for 2026-06-30 was $265.3M. Net income was $111.8M. ARVN currently screens at market cap $478.7M.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
ARVN currently screens at market cap $478.7M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the ARVN and BMRN stock pages for the full models.
Not investment advice.